Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network

Dhruti P. Chen,Margaret E. Helmuth,Abigail R. Smith,Pietro A. Canetta,Isabelle Ayoub,Krzysztof Mucha,Mahmoud Kallash,Jeffrey B. Kopp,Rasheed Gbadegesin,Brenda W. Gillespie,Larry A. Greenbaum,Rulan S. Parekh,Tracy E. Hunley,C. John Sperati,David T. Selewski,Jason Kidd,Aftab Chishti,Kimberly Reidy,Amy K. Mottl,Debbie S. Gipson,Tarak Srivastava,Katherine E. Twombley,Wooin Ahn,Gerald Appel,Paul Appelbaum,Revekka Babayev,Andrew Bomback,Brenda Chan,Vivette Denise D’Agati,Samitri Dogra,Hilda Fernandez,Ali Gharavi,William Hines,Syed Ali Husain,Namrata Jain,Krzysztof Kiryluk,Fangming Lin,Maddalena Marasa,Glen Markowitz,Hila Milo Rasouly,Sumit Mohan,Nicola Mongera,Jordan Nestor,Thomas Nickolas,Jai Radhakrishnan,Maya Rao,Simone Sanna-Cherchi,Shayan Shirazian,Michael Barry Stokes,Natalie Uy,Anthony Valeri,Natalie Vena,Bartosz Foroncewicz,Barbara Moszczuk,Agnieszka Perkowska-Ptasińska,Gian Marco Ghiggeri,Francesca Lugani,Josephine Ambruzs,Helen Liapis,Rossana Baracco,Amrish Jain,Isa Ashoor,Diego Aviles,Sun-Young Ahn,Prasad Devarajan,Elif Erkan,Donna Claes,Hillarey Stone,Sherene Mason,Liliana Gomez-Mendez,Chia-shi Wang,Hong Yin,Yi Cai,Goebel Jens,Julia Steinke,Donald Weaver,Jerome Lane,Carl Cramer,Cindy Pan,Neil Paloian,Rajasree Sreedharan,Corinna Bowers,Mary Dreher,John Mahan,Samantha Sharpe,William Smoyer,Amira Al-Uzri,Sandra Iragorri,Myda Khalid,Craig Belsha,Joseph Alge,Michael Braun,A.C. Gomez,Scott Wenderfer,Tetyana Vasylyeva,Daniel Feig,Gabriel Cara Fuentes,Melisha Hannah,Carla Nester,Jon Klein,Chryso Katsoufis,Wacharee Seeherunvong,Michelle Rheault,Craig Wong,Nisha Mathews,John Barcia,Agnes Swiatecka-Urban,Sharon Bartosh,Vikas Dharnidharka,Joseph Gaut,Louis-Philippe Laurin,Virginie Royal,Anand Achanti,Milos Budisavljevic,Sally Self,Cybele Ghossein,Yonatan Peleg,Shikha Wadhwani,Salem Almaani,Tibor Nadasdy,Samir,Parikh,Brad Rovin,Anthony Chang,Huma Fatima,Bruce Julian,Jan Novak,Matthew Renfrow,Dana Rizk,Vimal Derebail,Ronald Falk,Keisha Gibson,Dorey Glenn,Susan Hogan,Koyal Jain,J. Charles Jennette,Caroline Poulton,Manish Kanti Saha,Agnes Fogo,Neil Sanghani,Selvaraj Muthusamy,Jeffrey Schelling,Jean Hou,Kevin Lemley,Warren Mika,Pierre Russo,Michelle Denburg,Amy Kogon,Kevin Meyers,Madhura Pradhan,Raed Bou Matar,John O’Toole,John Sedor,Christine Sethna,Suzanne Vento,Mohamed Atta,Serena Bagnasco,Alicia Neu,Sharon Adler,Tiane Dai,Ram Dukkipati,Fernando Fervenza,Sanjeev Sethi,Frederick Kaskel,Kaye Brathwaite,Joseph Weisstuch,Ming Wu,Olga Zhdanova,Jurgen Heymann,Meryl Waldman,Cheryl Winkler,Katherine Tuttle,Jill Krissberg,Richard Lafayette,Kamal Fahmeedah,Elizabeth Talley,Michelle Hladunewich,Carmen Avila-Casado,Daniel Cattran,Reich Heather,Philip Boll,Yelena Drexler,Alessia Fornoni,Patrick Gipson,Jeffrey Hodgin,Andrea Oliverio,Jon Hogan,Lawrence Holzman,Matthew Palmer,Gaia Coppock,Blaise Abromovitz,Michael Mortiz,Charles Alpers,J. Ashley Jefferson,Elizabeth Brown,Kamal Sambandam,Bethany Roehm,Bruce Robinson,Cynthia Nast,Laura Barisoni,Matthias Kretzler,Laura Mariani,Lisa M. Guay-Woodford

DOI: https://doi.org/10.1053/j.ajkd.2022.11.012

IF: 11.072

2023-01-01

American Journal of Kidney Diseases

Abstract:RATIONALE & OBJECTIVE: <AbstractText Label="RATIONALE & OBJECTIVE">Adolescent- and adult-onset minimal change disease (MCD) may have a clinical course distinct from childhood-onset disease. We characterized the course of children and adults with MCD in the Cure Glomerulonephropathy Network (CureGN) and assessed predictors of rituximab response.</AbstractText>STUDY DESIGN: <AbstractText Label="STUDY DESIGN">Prospective, multicenter, observational study.</AbstractText>STUDY PARTICIPANTS: <AbstractText Label="STUDY PARTICIPANTS">CureGN participants with proven MCD on biopsy.</AbstractText>EXPOSURE: <AbstractText Label="EXPOSURE">Age at disease onset, initiation of renin-angiotensin-aldosterone system (RAAS) blockade, and immunosuppression including rituximab during the study period.</AbstractText>OUTCOME: <AbstractText Label="OUTCOME">Relapse and remission, change in estimated glomerular filtration rate (eGFR), and kidney failure.</AbstractText>ANALYTICAL APPROACH: <AbstractText Label="ANALYTICAL APPROACH">Remission and relapse probabilities were estimated using Kaplan-Meier curves and gap time recurrent event models. Linear regression models were used for the outcome of change in eGFR. Cox proportional hazards models were used to estimate the association between rituximab administration and remission.</AbstractText>RESULTS: <AbstractText Label="RESULTS">The study included 304 childhood- (≤12 years old), 49 adolescent- (13-17 years old), and 201 adult- (≥18 years) onset participants with 2.7-3.2 years of follow-up after enrollment. Children had a longer time to biopsy (238 vs 23 and 36 days in adolescent- and adult-onset participants, respectively; P<0.001) and were more likely to have received therapy before biopsy. Children were more likely to be treated with immunosuppression but not RAAS blockade. The rate of relapse was higher in childhood- versus adult-onset participants (HR, 1.69 [95% CI, 1.29-2.21]). The probability of remission was also higher in childhood-onset disease (HR, 1.33 [95%CI, 1.02-1.72]). In all groups eGFR loss was minimal. Children were more likely to remit after rituximab than those with adolescent- or adult-onset disease (adjusted HR, 2.1; P=0.003). Across all groups, glucocorticoid sensitivity was associated with a greater likelihood of achieving complete remission after rituximab (adjusted HR, 2.62; P=0.002).</AbstractText>LIMITATIONS: <AbstractText Label="LIMITATIONS">CureGN was limited to biopsy-proven disease. Comparisons of childhood to nonchildhood cases of MCD may be subject to selection bias, given that childhood cases who undergo a biopsy may be limited to patients who are least responsive to initial therapy.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">Among patients with MCD who underwent kidney biopsy, there were differences in the course (relapse and remission) of childhood-onset compared with adolescent- and adult-onset disease, as well as rituximab response.</AbstractText>PLAIN-LANGUAGE SUMMARY: <AbstractText Label="PLAIN-LANGUAGE SUMMARY">Minimal change disease is a biopsy diagnosis for nephrotic syndrome. It is diagnosed in childhood, adolescence, or adulthood. Patients and clinicians often have questions about what to expect in the disease course and how to plan therapies. We analyzed a group of patients followed longitudinally as part of the Cure Glomerulonephropathy Network (CureGN) and describe the differences in disease (relapse and remission) based on the age of onset. We also analyzed rituximab response. We found that those with childhood-onset disease had a higher rate of relapse but also have a higher probability of reaching remission when compared with adolescent- or adult-onset disease. Children and all steroid-responsive patients are more likely to achieve remission after rituximab.</AbstractText>

urology & nephrology